Protagenic Therapeutics, Inc. (PTIX)
NASDAQ: PTIX · Real-Time Price · USD
0.591
-0.031 (-5.03%)
Nov 21, 2024, 10:06 AM EST - Market open
Protagenic Therapeutics Employees
As of December 31, 2023, Protagenic Therapeutics had 3 total employees, including 1 full-time and 2 part-time employees. The number of employees increased by 2 or 200.00% compared to the previous year.
Employees
3
Change
2
Growth
200.00%
Revenue / Employee
n/a
Profits / Employee
-$1,882,595
Market Cap
2.64M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3 | 2 | 200.00% |
| Dec 31, 2015 | 1 | 0 | - |
| Dec 31, 2014 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Regional Health Properties | 114 |
| Fresh2 Group | 75 |
| Molecular Templates | 62 |
| Matinas BioPharma Holdings | 32 |
| Scinai Immunotherapeutics | 31 |
| ReShape Lifesciences | 29 |
| ENDRA Life Sciences | 21 |
| Petros Pharmaceuticals | 21 |
PTIX News
- 16 days ago - Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million - Accesswire
- 23 days ago - Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million - Accesswire
- 7 months ago - Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial - Accesswire
- 7 months ago - Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit - Accesswire
- 8 months ago - Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript - Seeking Alpha
- 8 months ago - Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results - Accesswire
- 8 months ago - Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders - Accesswire
- 8 months ago - Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call - Accesswire